Attached files

file filename
EX-99.1 - PRESS RELEASE - PAR PHARMACEUTICAL COMPANIES, INC.f8212q22012earningsresults.htm



SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

______________________


FORM 8-K


CURRENT REPORT


PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934


Date of report (Date of earliest event reported):  August 2, 2012


PAR PHARMACEUTICAL COMPANIES, INC.

(Exact name of registrant as specified in its charter)



Delaware

File Number 1-10827

22-3122182

(State or other jurisdiction of

(Commission File Number)

(I.R.S. Employer

incorporation or organization)


Identification No.)






300 Tice Boulevard, Woodcliff Lake, NJ

07677

   (Address of principal executive offices)

(Zip Code)


Registrants telephone number, including area code: (201) 802-4000


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))






1


Item 2.02   Results of Operations and Financial Condition.


On August 2, 2012, Par Pharmaceutical Companies, Inc. issued a press release announcing its financial results for the first quarter ended June 30, 2012.  The Companys press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.


The information in this Current Report on Form 8-K, including Exhibit 99.1, is furnished pursuant to Item 2.02 and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.  


Item 9.01

Financial Statements and Exhibits.


(d)

The following exhibit is furnished with this Current Report on Form 8-K:


 

 

 

 

Exhibit No.

     

                 Description

99.1

 

                 Press Release dated August 2, 2012


Certain statements in this Current Report on Form 8-K constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent that any statements made in this Current Report on Form 8-K contain information that is not historical, such statements are essentially forward-looking and are subject to certain risks and uncertainties, including the risks and uncertainties discussed from time to time in the Companys filings with the SEC, including its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements included in this Current Report on Form 8-K are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.




2


SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



Dated as of:  August 2, 2012



PAR PHARMACEUTICAL COMPANIES, INC.

(Registrant)




/s/ Michael A. Tropiano

Michael A. Tropiano, Executive Vice President and

Chief Financial Officer





3


EXHIBIT INDEX



     The following exhibit is furnished with this Current Report on Form 8-K:


 

 

 

 

Exhibit No.

 

              Description

99.1

 

              Press Release dated August 2, 2012





4